Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASCO 2018

ALL

View all
3:13
Tisagenlecleucel in ALL: follow-up data and insights
Stephan Grupp • 1 Jun 2018
2:31
Improving the SOC for ALL with inotuzumab
Ryan Cassaday • 1 Jun 2018

AML

View all
1:44
A worldwide Phase III trial treating AML with pracinostat
Guillermo Garcia-Manero • 1 Jun 2018
1:48
IDH1 inhibitor ivosidenib for the treatment of relapsed/ refractory AML
Daniel Pollyea • 1 Jun 2018

CLL

View all
3:30
Moxetumomab pasudotox and hairy cell leukemia: results of a pivotal study
Robert Kreitman • 1 Jun 2018
1:46
Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
Peter Hillmen • 1 Jun 2018

Lymphoma

View all
1:32
Choosing the best treatment for your follicular lymphoma patient
Nathan Fowler • 1 Jun 2018
5:52
Updated safety & durability results for CAR-T lisocabtagene maraleucel in NHL
Jeremy Abramson • 1 Jun 2018

MM

View all
2:29
10 years of researching NK-cells for MM treatment
Nina Shah • 1 Jun 2018
5:20
Immuno-oncology agents for MM: checkpoint inhibitors and NK-cells
Noopur Raje • 1 Jun 2018

Clinical Trial Updates

View all
1:54
FORTE update: carfilzomib-lenalidomide induction therapy for MM
Francesca Gay • 1 Jun 2018
2:54
ARROW: once vs. twice weekly carfilzomib for MM
Maria Victoria-Mateos • 1 Jun 2018
The content of VJHemOnc is intended for healthcare professionals